{"id":"nct:NCT01900665","kind":"trial","title":"Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo","authors":["Eli Lilly and Company"],"author_count":1,"year":2013,"published":"2013-07-16","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT01900665","source_url":"https://clinicaltrials.gov/study/NCT01900665","archive_url":"https://space-kitty.com/papers/nct:NCT01900665","updated":"2019-10-09","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Alzheimer's Disease"],"details":{"acronym":"EXPEDITION 3","status":"TERMINATED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":2129,"sponsor":"Eli Lilly and Company","conditions":["Alzheimer's Disease"],"interventions":["DRUG: Solanezumab","DRUG: Placebo"],"start_date":"2013-07-01","start_date_type":null,"primary_completion_date":"2016-10-01","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}